Simala-Grant JL et al. |
Antibiotic susceptibility of attached and free-floating Helicobacter pylori. |
2001 |
J. Antimicrob. Chemother. |
pmid:11328765
|
Martin SJ et al. |
The activity of 14-hydroxy clarithromycin, alone and in combination with clarithromycin, against penicillin- and erythromycin-resistant Streptococcus pneumoniae. |
2001 |
J. Antimicrob. Chemother. |
pmid:11328768
|
Warburton-Timms VJ and McNulty CA |
Role of screening agar plates for in vitro susceptibility testing of Helicobacter pylori in a routine laboratory setting. |
2001 |
J. Clin. Pathol. |
pmid:11328845
|
Baffone W et al. |
Studies on the development and stability of resistance of Helicobacter pylori to metronidazole and clarithromycin. |
2001 |
J Chemother |
pmid:11330358
|
Eltahawy AT |
Antimicrobial resistance of Streptococcus pneumoniae at a university hospital in Saudi Arabia. |
2001 |
J Chemother |
pmid:11330361
|
Lin Z et al. |
Prevalence of gastric myoelectrical abnormalities in patients with nonulcer dyspepsia and H. pylori infection: resolution after H. pylori eradication. |
2001 |
Dig. Dis. Sci. |
pmid:11330406
|
Matsuoka M et al. |
A Mycobacterium leprae isolate resistant to dapsone, rifampin, ofloxacin and sparfloxacin. |
2000 |
Int. J. Lepr. Other Mycobact. Dis. |
pmid:11332288
|
Xia HH et al. |
Helicobacter pylori infection--current treatment practice. |
2001 |
Expert Opin Pharmacother |
pmid:11336584
|
Samra Z et al. |
In vitro susceptibility of recent clinical isolates of Chlamydia trachomatis to macrolides and tetracyclines. |
2001 |
Diagn. Microbiol. Infect. Dis. |
pmid:11337185
|
Stein GE and Schooley S |
Comparative serum bactericidal activity of clarithromycin and azithromycin against macrolide-sensitive and resistant strains of Streptococcus pneumoniae. |
2001 |
Diagn. Microbiol. Infect. Dis. |
pmid:11337186
|
Alou L et al. |
Evaluation of two in vitro pharmacodynamic simulation models: microfiltration versus centrifugation-filtration. |
2001 |
Int. J. Antimicrob. Agents |
pmid:11337222
|
Ferrara A et al. |
Effect of different antibacterial agents and surfactant protein-A (SP-A) on adherence of some respiratory pathogens to bronchial epithelial cells. |
2001 |
Int. J. Antimicrob. Agents |
pmid:11337228
|
Larkin CJ et al. |
Gastric corpus atrophy following eradication of Helicobacter pylori. |
2001 |
Eur J Gastroenterol Hepatol |
pmid:11338065
|
Drinkard CR et al. |
Postmarketing surveillance of medications and pregnancy outcomes: clarithromycin and birth malformations. |
2000 |
Pharmacoepidemiol Drug Saf |
pmid:11338912
|
Stock I and Wiedemann B |
Natural antibiotic susceptibility of Klebsiella pneumoniae, K. oxytoca, K. planticola, K. ornithinolytica and K. terrigena strains. |
2001 |
J. Med. Microbiol. |
pmid:11339246
|
Sotudehmanesh R et al. |
A randomized controlled comparison of three quadruple therapy regimens in a population with low Helicobacter pylori eradication rates. |
2001 |
J. Gastroenterol. Hepatol. |
pmid:11339416
|
Currier JS et al. |
Impact of prophylaxis for Mycobacterium avium complex on bacterial infections in patients with advanced human immunodeficiency virus disease. |
2001 |
Clin. Infect. Dis. |
pmid:11340534
|
Osato MS et al. |
Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. |
2001 |
Arch. Intern. Med. |
pmid:11343444
|
Asencio Marchante R and Lissen Otero E |
[Secondary prevention of opportunistic infections in HIV-infected patients]. |
2001 |
Rev Clin Esp |
pmid:11345612
|
Neville PM et al. |
Randomised study of the efficacy of omeprazole and clarithromycin with either amoxycillin or metronidazole in the eradication of Helicobacter pylori in screened primary care patients. |
2001 |
Dig Liver Dis |
pmid:11346140
|
Gill J and Feinberg J |
Saquinavir soft gelatin capsule: a comparative safety review. |
2001 |
Drug Saf |
pmid:11347724
|
Dresser LD et al. |
Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia. |
2001 |
Chest |
pmid:11348951
|
Akritopoulou-Zanze I and Sowin TJ |
Solid-phase synthesis of macrolide analogues. |
2001 May-Jun |
J Comb Chem |
pmid:11350254
|
Hiyama T et al. |
Helicobacter pylori eradication therapy for high-grade mucosa-associated lymphoid tissue lymphomas of the stomach with analysis of p53 and K-ras alteration and microsatellite instability. |
2001 |
Int. J. Oncol. |
pmid:11351252
|
Afghani B and Fujiyama D |
Use of potassium tellurite for rapid-drug susceptibility testing of Mycobacterium avium complex. |
2001 |
J. Investig. Med. |
pmid:11352188
|
Nash KA |
Effect of drug concentration on emergence of macrolide resistance in Mycobacterium avium. |
2001 |
Antimicrob. Agents Chemother. |
pmid:11353601
|
Guay DR et al. |
Pharmacokinetics and tolerability of extended-release clarithromycin. |
2001 |
Clin Ther |
pmid:11354390
|
Adam D et al. |
Comparative efficacy of clarithromycin modified-release and clarithromycin immediate-release formulations in the treatment of lower respiratory tract infection. |
2001 |
Clin Ther |
pmid:11354392
|
Capella GL et al. |
A randomized trial of leukotriene receptor antagonist montelukast in moderate-to-severe atopic dermatitis of adults. |
2001 May-Jun |
Eur J Dermatol |
pmid:11358726
|
Kaplan EL et al. |
Macrolide therapy of group A streptococcal pharyngitis: 10 days of macrolide therapy (clarithromycin) is more effective in streptococcal eradication than 5 days (azithromycin). |
2001 |
Clin. Infect. Dis. |
pmid:11360224
|
|
Clarithromycin for MAC. |
1995 |
AIDS Patient Care |
pmid:11361361
|
|
NIAID study rules out high-dose clarithromycin for AIDS-related MAC. |
1996 |
AIDS Patient Care STDS |
pmid:11361534
|
|
New data suggest antibiotic clarithromycin is effective in prolonging life of AIDS patients. |
1996 |
AIDS Patient Care STDS |
pmid:11361575
|
|
Clarithromycin and MAC. |
1996 |
AIDS Patient Care STDS |
pmid:11361673
|
|
Different clarithromycin doses affect mortality. |
1997 |
AIDS Patient Care STDS |
pmid:11361754
|
Cheng B |
Preventing opportunistic infections. |
1995 |
PI Perspect |
pmid:11362422
|
|
Abbott files SNDA for MAC prophylaxis. |
1995 |
J Int Assoc Physicians AIDS Care |
pmid:11362606
|
Pierce M |
Another perspective on MAC prophylaxis. Interview by Gordon Nary. |
1995 |
J Int Assoc Physicians AIDS Care |
pmid:11362746
|
Archange YR et al. |
Clarithromycin prophylaxis against disseminated Mycobacterium avium complex in patients with AIDS. |
1995 |
J Int Assoc Physicians AIDS Care |
pmid:11362747
|
|
Physician's aggressive preventive therapy differs. |
1995 |
AIDS Alert |
pmid:11362774
|
|
New drug applications sought. |
1995 |
AIDS Alert |
pmid:11362777
|
Smart T |
Cryptosporidiosis at ICAAC. |
1995 |
GMHC Treat Issues |
pmid:11362913
|
|
Researchers find new drugs to fight MAC. |
1995 |
AIDS Alert |
pmid:11362925
|
|
FDA approves Biaxin for MAC prophylaxis. Food and Drug Administration. |
1995 |
J Int Assoc Physicians AIDS Care |
pmid:11363096
|
Prescott LM |
Clarithromycin for MAC prevention offers additional benefits. |
1996 May-Jun |
Posit Aware |
pmid:11363431
|
Young A |
Hold the big MAC. |
1996 |
Notes Undergr |
pmid:11363450
|
|
High-dose clarithromycin should be avoided. |
1996 |
AIDS Alert |
pmid:11363723
|
|
Pot shots. |
1996 |
Notes Undergr |
pmid:11363915
|
Bowersox J |
CPCRA researchers present OI studies at Vancouver. |
1996 |
NIAID AIDS Agenda |
pmid:11363924
|
|
MAC management. |
1996 |
PI Perspect |
pmid:11363967
|